jRCT2013190010已完成不适用
Intravenous infusion of autologous mesenchymal stem cells (MSC) from bone marrow for Amyotrophic lateral sclerosis (ALS) patients: double-blind randomized controlled trial (STR01-09)
未提供0 个研究点目标入组 40 人开始时间: 2020年9月25日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- ALSFRS-R change ratio
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Crossover Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 80age old not（—）
- 性别
- All
入选标准
- •[Inclusion criteria at the time of first registration]
- •(1) ALS that meets the diagnostic criteria (Updete Awaji ) as definite or probable
- •(2) ALS Severity is class1 to 3
- •(3) ALS onset within 3 years
- •(4) %FVC greater than or equal to 70%
- •(5) Completion of this trial is expected
- •(6) Age between 20 to 80
- •(7) The written informed consent obtained as much as possible from subjects. If the subject does not have ability to write etc, the written informed consent obtained from legal representative.
- •[Inclusion criteria at the time of second registration]
- •(1) ALS Severity is class1 to 3
- •(2) %FVC greater than or equal to 70%
- •(3) Completion of this trial is expected
- •(4) Ready to infuse of investigational product which satisfies specification of acceptance criteria
- •(5) Standard treatment (Riluzole, Edaravone,etc.) is not scheduled to change
排除标准
- •[Exclusion criteria at the time of first registration]
- •(1) Bulbar paralysis related ALS or uncontrollable mental symptoms
- •(2) Diagnosed as dementia
- •(3) Diagnosed as HBV, HCV, HIV, HTLV-1, syphilis or Human parvovirus B19 by initial screening
- •(4) Pancytopenia (WBC <2000/uL, Hb <10.0g/dl, Plt <100000/uL)
- •(5) Past history of neoplasms (except CR), severe diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, severe mental and behavioural disorders, severe diseases of the nervous system, severe congenital malformations, deformations and chromosomal abnormalities
- •(6) Past history of penicillin and streptomycin allergy or other severe allergy (shock, anaphylactoid symptoms etc.)
- •(7) Poor general condition due to [Endocrine, nutritional and metabolic diseases, Mental disorders, diseases of nervous system, diseases of circulatory system (Uncontrollable and refractory heart failure, moderate or severe valvular heart disorder, uncontrollable and refractory atrial fibrillation, refractory atrial and ventricular thrombus, history of ischemic heart disease and PCI within the past 12 months, serious arrhythmia), diseases of the respiratory system, diseases of the digestive system, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system (dialysis etc), injury, poisoning and certain other consequences of external causes etc]
- •(8) Intracranial lesion (severe asymptomatic lesion, severe old infarction, severe white matter lesion, severe multiple lesions, severe microbleeding or multiple hemosiderosis, Cerebrovascular diseases such as Moyamoya disease or high risk AN etc, severe intracerebral hemorrhage etc) including past history of these issues.
- •(9) 70% or more stenosis or dissecting in the artery causing cerebral infarction even though after revascularization (except complete thrombotic occlusion)
- •(10) Severe arteriosclerotic change and calcification in the blood vessels of head and neck.
- •(11) Preoperative possible uncontrollable HT under depressor therapy (systolic pressure more than 140mmHg, diastolic pressure more than 90mmHg)
- •(12) Participation in other clinical trials or past history of cellular therapy
- •(13) Pregnant or possibly pregnant, nursing women or those who plan to be pregnant during the study period or male patients who wish partner to get pregnant
- •(14) Other patients judged by investigators as inappropriate for this study
- •[Exclusion criteria at the time of second registration]
- •(1) Past history of neoplasms (except CR), severe diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, severe mental and behavioural disorders, severe diseases of the nervous system, severe congenital malformations, deformations and chromosomal abnormalities
- •(2) Past history of penicillin and streptomycin allergy or other severe allergy (shock, anaphylactoid symptoms etc.)
- •(3) Poor general condition due to [Endocrine, nutritional and metabolic diseases, Mental disorders, diseases of nervous system, diseases of circulatory system (Uncontrollable and refractory heart failure, moderate or severe valvular heart disorder, uncontrollable and refractory atrial fibrillation, refractory atrial and ventricular thrombus, history of ischemic heart disease and PCI within the past 12 months, serious arrhythmia), diseases of the respiratory system, diseases of the digestive system, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system (dialysis etc), injury, poisoning and certain other consequences of external causes etc]
- •(4) Intracranial lesion (moderate asymptomatic lesion, old infarction, white matter lesion, multiple lesions, microbleeding or multiple hemosiderosis, Cerebrovascular diseases such as Moyamoya disease or AN etc, severe intracerebral hemorrhage etc)
- •(5) 70% or more of stenosis or dissecting in the artery causing cerebral infarction even though after revascularization (except complete thrombotic occlusion)
- •(6) Severe arteriosclerotic change and calcification
- •(7) Preoperative possible uncontrollable hypertension under depressor therapy
- •(8) Pregnant, nursing women or those who plan to be pregnant during the study period or male patients who wish partner to get pregnant
- •(9) Other patients judged by investigators as inappropriate for this study
结局指标
主要结局
ALSFRS-R change ratio
时间窗: 3 months before and after 90 days after first enrollment
The difference of change ratio of ALSFRS-R during 3 months before and after 90 days after first enrollment
次要结局
- Difference of change ratio of MMT, grasping power, Norris scale, ALSAQ-40, %FVC
- Difference of change ratio of ALSFRS-R, MMT, grasping power, Norris scale, ALSAQ-40, %FVC between 90days and 180days after enrollment(90days and 180days after enrollment)
- Difference of change ratio of ALSFRS-R, MMT, grasping power, Norris scale, ALSAQ-40, %FVC between 90days and 270days after enrollment(90days and 270days after enrollment)
- Difference of change ratio of ALSFRS-R, MMT, grasping power, Norris scale, ALSAQ-40, %FVC at 3 months before enrollment and at 6months after enrollment(3 months before enrollment and 6months after enrollment)
- Difference of change ratio of ALSFRS-R, MMT, grasping power, Norris scale, ALSAQ-40, %FVC at 3months before and after injection of the investigational product(3months before and after injection of the investigational product)
- All adverse events rate during whole study period(whole study period)
研究者
相似试验
招募中
2 期
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for chronic brain injury patients (PhaseII)Chronic brain injuryJPRN-jRCT1090220333Osamu Honmou, MD, PhD10
招募中
2 期
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for ALS patients: double-blind randomized controlled trialAmyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis, ALSD000690JPRN-jRCT2013190010HISAHARA SHI40
尚未招募
2 期
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for dementia patients: open-label trialDementiaJPRN-jRCT1090220332Chiaki Kawanishi, MD, PhD20
尚未招募
2 期
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for dementia patients: randomized controlled open-label trialDementiaJPRN-jRCT1090220331Chiaki Kawanishi, MD, PhD10
招募中
2 期
Intravenous infusion of autologous mesenchymal stem cells from bone marrow for chronic stroke patients (Phase II)Chronic strokeJPRN-jRCT1090220330Osamu Honmou, MD, PhD10